Ginkgo Bioworks (DNA) news
Recent news
Cronos Group 1Q EPS 4.0c
Cronos Group Inc. (NASDAQ:CRON) reported first-quarter earnings per share of 4.0 cents for the period ending March 31, 2026. The Canadian cannabis company, which operates across the full value chain of cannabis cultivation, production, and distribution, continues to focus on innovation and…
AInvest Wire · May 11, 2026ImportantGinkgo Bioworks to sell its biosecurity unit to investors
AInvest Wire · Feb 26, 2026AMD RDNA 4 “Radeon RX 8000” GPUs reportedly debut in 2025: Navi 48 at CES & Navi 44 in Q2
AInvest Wire · Jul 6, 2024Ginkgo Bioworks expects to meet 2023 new program & rev guidance.
Ginkgo Bioworks expects to meet 2023 new program & rev guidance. Ginkgo Bioworks, a biotechnology company focused on cell programming and biosecurity, has announced that it expects to meet its 2023 new program and revenue guidance [1]. In the third quarter of 2023, the company added 21 new Cell…
AInvest Wire · Jan 10, 2024Ginkgo Bioworks announced the successful completion of the gene therapy collaboration with Biogen to boost productivity of gene therapy manufacturing platform
Ginkgo Bioworks announced the successful completion of the gene therapy collaboration with Biogen to boost productivity of gene therapy manufacturing platform Ginkgo Bioworks, a company known for its expertise in cell programming and biosecurity, has announced the successful completion of its gene…
AInvest Wire · Jan 4, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.